bluebird bio Inc (BLUE)
0.5044
+0.01
(+1.39%)
USD |
NASDAQ |
Sep 27, 16:00
0.5045
0.00 (0.00%)
After-Hours: 20:00
bluebird bio Research and Development Expense (TTM): 146.58M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 146.58M |
| December 31, 2023 | 163.10M |
| September 30, 2023 | 134.90M |
| June 30, 2023 | 142.58M |
| March 31, 2023 | 164.15M |
| December 31, 2022 | 200.44M |
| September 30, 2022 | 274.25M |
| June 30, 2022 | 294.78M |
| March 31, 2022 | 315.58M |
| December 31, 2021 | 320.55M |
| September 30, 2021 | 109.61M |
| June 30, 2021 | 176.37M |
| March 31, 2021 | 248.03M |
| December 31, 2020 | 319.31M |
| September 30, 2020 | 357.39M |
| June 30, 2020 | 368.37M |
| March 31, 2020 | 358.60M |
| December 31, 2019 | 327.12M |
| September 30, 2019 | 540.31M |
| June 30, 2019 | 505.65M |
| March 31, 2019 | 474.12M |
| December 31, 2018 | 448.59M |
| September 30, 2018 | 421.44M |
| Date | Value |
|---|---|
| June 30, 2018 | 366.24M |
| March 31, 2018 | 315.12M |
| December 31, 2017 | 273.04M |
| September 30, 2017 | 237.60M |
| June 30, 2017 | 240.02M |
| March 31, 2017 | 217.89M |
| December 31, 2016 | 204.78M |
| September 30, 2016 | 183.30M |
| June 30, 2016 | 149.72M |
| March 31, 2016 | 152.23M |
| December 31, 2015 | 134.04M |
| September 30, 2015 | 118.91M |
| June 30, 2015 | 105.16M |
| March 31, 2015 | 74.83M |
| December 31, 2014 | 62.57M |
| September 30, 2014 | 51.81M |
| June 30, 2014 | 43.86M |
| March 31, 2014 | 37.18M |
| December 31, 2013 | 31.00M |
| September 30, 2013 | 27.73M |
| June 30, 2013 | 22.53M |
| March 31, 2013 | 18.64M |
| December 31, 2012 | 17.21M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
109.61M
Minimum
Sep 2021
540.31M
Maximum
Sep 2019
261.16M
Average
274.25M
Median
Sep 2022
Research and Development Expense (TTM) Benchmarks
| Vertex Pharmaceuticals Inc | 3.390B |
| Perspective Therapeutics Inc | 28.53M |
| Protalix BioTherapeutics Inc | 12.62M |
| Predictive Oncology Inc | -- |
| Spectral AI Inc | -- |